Anexo A – Parecer consubstanciado do Comitê de Ética e Pesquisa do HCFMUSP
Anexo B (frente) - Ficha de Notificação e Atendimento do CEATOX-ICr- HCFMUSP
CEATOX – CENTRO DE ASSISTÊNCIA TOXICOLÓGIA - ICr-HC FMUSP Ficha de Notificação e Atendimento
Nº :________________ DATA: ____/_____/______ HORA:___________________ TELEFONE Nº: _____________ IDENTIFICAÇÃO DO PACIENTE:
Nome:________________________________________________________________________________________________________________ Idade:______ (D, M, A) Sexo: (1)Masc. (2)Fem. (9)Ignorado Gestante: ______trimestre Vítima: (1)Humana
Profissão/Ocupação:_____________________________________________ Peso: _____ Kg (2)Animal
Endereço:________________________________________________________________Telefone:________________ (3)Informação Bairro:______________________________________________________ Município: ______________________________ Estado:____________ IDENTIFICAÇÃO DO NOTIFICANTE: Nome:___________________________________________________________________________Instituição:____________________________
Endereço: ________________________________________________________________________ Telefone:_____________________________ Bairro: _________________________________________________ Município: _________________________________Estado: _____________ (1) Próprio (2) Médico (3) Parente (4) Veterinário (5) Outro prof. Saúde (9) Ignorada (8) outro:___________________________________ ATENDIMENTO TELEFÔNICO HOSPITALAR (1)Hosp/Clínicas (1)PS (2)CS/UBS (2)Enfermaria (3)Consult./Ambul. (3)Ambulatório (4)Local Trabalho (4)Outro:__________ (5)Outros CIT (6)Outros Serv. Público:_________________ (7)Residência (8)Outro (9)Ignorado TIPO DE OCORRÊNCIA (1) Intoxicação (2) Exposição (3) Reação Adversa (4) Diagnóstico Diferencial (8) Outro: _____________________ (9) Ignorado CIRCUNSTÂNCIA (1)Acidente Individual (9)Abstinência (2)Acidente Coletivo (10)Abuso (3)Acidente Ambiental (11)Ingest. Alimentos (4)Ocupacional (12)Tentativa de Suicídio (5)Uso Terapêutico (13)Tentativa de Aborto (6)Presc. Méd. Inadequada (15)Violência/Homicídio (7)Erro de Administração (99)Ignorada (8)Auto Medicação (88) Outra:__________ (14) Uso inadequado ZONA (1)Urbana (2)Rural LOCAL (1)Residência (6)Escola/Creche (2)Ambiente de Trabalho (7)Ambiente ext. (3)Via/Área Pública (8)Outro:__________ (4)Serv. De Saúde (9)Ignorado (5)Trajeto de trabalho Endereço:_________________________________ EXPOSIÇÃO – VIA (1)Oral (99)Ignorada (2) Cutânea (88)Outra (3)Respiratória (4)Parenteral (5)Nasal (6)Ocular (7)Retal (8)Vaginal (9)Mordedura/picada TIPO (1)Aguda – única (2)Aguda – repetida (3)Crônica (4)Agudo sobre crônica (9)Ignorada Tempo decorrido da exposição:_____________ Duração da exposição:____________________ AGENTE TÓXICO NOME (COMERCIAL) FABRICANTE DOSE/ QUANTIDADE PRINCIPIOS ATIVOS (1) Medicamentos (2) Agrotóxicos/ Uso Agrícola (3) Agrotóxicos/ Uso Domestico (4) Produtos Veterinários (5)Raticidas
(6)Saneantes Domésticos
(7)Cosméticos (8)Produtos Quím. Industr.
(9)Metais (10)Drogas (11)Plantas (12)Alimentos (13)Animais peçonhentos/serpentes
(14)Animais peçonhentos / aranhas (15)Anim. peçonhentos/escorpiões (16)Outros anim. Peçonhentos
(17)Animais não peçonhentos (99)Desconhecido
(88)Outro:
EVOLUÇÃO
MANIFESTAÇÃO CLÍNICA: (1) SIM (2)NÃO INTERNAÇÃO: (1) SIM (2) NÃO (9) IGNORADO ANÁLISE TOXICOLÓGICA: (1) SIM (2) NÃO SUBSTÂNCIA:_________________________________________________ EVOLUÇÃO: (1)Cura (2)Cura não confirmada (3)Sequela (4)Óbito (5)Óbito outra causa (8)Outro:______________ (9)Ignorado DIAGNÓSTICO DEFINITIVO:____________________________________________________________________________________________
Anexo B (verso) – Ficha de Notificação e Atendimento do CEATOX-ICr- HCFMUSP
Anexo C – Distribuição dos medicamentos associados aos EM na população pediátrica no ambiente domiciliar classificados de acordo com o sistema ATC (1o e 2o nível) notificados entre janeiro e maios de 2016
A02: Distúrbios gástricos relacionados à acidez 6 A03: Distúrb funcionais (antiespasm, psicolépt, analgés 29 A04: Antieméticos e antinauseantes 5 A07: Antidiarreicos, antiiflamatórios e antiinfec intest 10 A10: Medicamentos usados em diabetes 3
A11: Vitaminas 16
A12: Suplementos minerais 3
72 (13,7) B: Sangue e órgãos hematopoiéticos B03: Antianêmicos 6 Sub-total 6 (1,1) C02:Antihipertensivos 1 C03: Diuréticos 1
C09: Medicamentos que atuam no sist renina- angiot 1 C10: Medicamentos antilipêmicos 2
Sub-total 5 (1,0)
D01: Antifúngicos tópicos e sistêmicos 5 D03: Medicamentos para lesões e úlceras 2 D04: Antipruriginosos, incluindo antihistam 1 D06: Antibióticos e quimiot para uso dermatol 1 D07: Corticosteróides 2 D08: Antissépticos e desinfectantes 3
D09: Curativos 1
D11: Outros prep para uso dermatol 1
16 (3,0)
G02: Outros preparados ginecológicos 4
G03: Hormônios sexuais e modul do sist reprod 2
G04: Medicamentos urológicos 1
Sub-total 7 (1,3)
H02: Corticosteróides para uso sistêmico 6 H03: Terapêutica tiroideana 3
9 (1,7)
J01: Antibacterianos para uso sistêmico 45 J05: Antiretrovirais para uso sistêmico 2
J07: Vacinas 3 50 (9,5) L - Antineoplás e Imunomodul L02 - Endócrinos 1 Sub-Total 1 (0,2) M: Sistema músculo
esquelético M01: Antinflamatórios e Anti-reumáticos 9
9 (1,7)
N02: Analgésicos 51
N03: Anticonvulsivantes 24
N05: Psicolépticos 17
N06: Psicoanalépticos 3 N07: Outros medicamentos do sistema nervoso 2
97 (18,4)
P01: Antiprotozoários 9
P02: Anti-helmíntico 7
P03: Ectoparasit, incluindo escabic, insetic e repel 2
Sub-total 18 (3,4)
R01: Medicamentos para uso nasal 47 R02: Medicamentos para uso em orofaringe 16 R03: Medicamentos para obstrução das vias aéreas 87 R05: Antitussígenos e sintomas do resfriado 14 R06: Anti-histamínicos para uso sistêmico 48
Sub-total 212 (40,2) S01: Produtos oftalmológicos 13 S02: Produtos otológicos 12 Sub-total 25 (4,7) TOTAL 527 (100,0) P: Antiparasitários, insetic e repel R: Aparelho respiratório A: Sistema digestivo e metabolismo J: Antiinfecciosos para uso sistêmico Sub-total D: Dermatológicos C: Sistema cardiovascular S: Órgãos do sentido G: Sistema genito- urinário e hormônios sexuais H: Sistema hormonal, excl. hormôn. sex e insul Sub-total Sub-total Sub-total N: Sistema nervoso Sub-total Sub-total n %
1. World Health Organization WHO. Reporting and learning systems for medication errors: the role of pharmacovigilance centre. France: WHO Press, 2014. 96p.
2. Runciman W, Hibbert P, Thomson R, Chaaf TVD, Sherman H, Lewale P. Towards an international classification for patienty safety: key concepts and terms. Int J Qual Health Care. 2009;21(1):18-26.
3. Sheikh A, Dhingra-Kumar N, Kelley E, Dieny MP, Donaldson LJ. The third global patient safety challenge: tackling medication-related harm [editorial]. Bull World Health Organ. 2017; 95(8):546-546A.
4. Kohn L, Corrigan JM, Donaldson MS. To Err is Human: Building a Safer Health System. Committee on Quality of Health Care in America. Institute of Medicine. Washington D.C.: National Academy Press; 2000. 312p.
5. Jha AK, Prasopa-Plaizier N, Larizgoitia I, Bates DW. Patient safety research: an overview of the global evidence. Qual Saf Health Care. 2012;19(1):42-7.
6. Makary MA, Daniel M. Medical error - the third leading cause of death in the US. BMJ. 2016;353:i2139.
7. Leape LL. Error in Medicine. JAMA. 1994; 27(23):1851-7.
8. Grober ED, Bohnem JMA. Defining medical error. Can J Surg. 2005;48(1):39-44.
9. Ferner RE, Aronson JK. Clarification of terminology in medication error: definitions and classification. Drug Saf. 2006;29(11):1011-22.
10. Ferner RE. Harms from medicines: inevitable, in error or intentional. Br J Clin Pharmacol. 2014;77(3):403-9.
11. Wittch CM, Burkle CM, Lanier WL. Medications errors : an overview for clinicians. Mayo Clin Proc. 2014;89(8):1116-25.
12. Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication without harm: WHO’s third global patient safety challenge. Lancet. 2017;389(10080):1680-1.
13. Härkanen M, Vehviläinen-Julkunen K, Murrells T, Rafferty AM, Franklin BD. Medication administration errors and mortality: incidents reported in England and Wales between 2007-2016. Rev Social Adm Pharm. 2018; pii:S155-7411(18)30635-1.
14. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Frederico F, Leape LL, Bates DW. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556-64.
15. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136-47.
16. Cohen A, Budnitz DS, Weidenbach KN, Jernigan dB, Schorerder TJ, Shehab N, Pollock DA. National surveillance of emergencie department
visits for outpatient adverse drug events in children and adolescents. J Pediatr. 2008;152(3):416-21.
17. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7- 8):977-89.
18. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013- 2014. JAMA.2016;316(20):2115-2125.
19. Rosafio C, Paioli S, Giovane CD, Cenciarelli V, Viani N, Bertolani P, Lughetti L. Medication-related visits in a pediatric emergency department: an 8-years retrospective analysis. Ital J Pediatr. 2017;43(1):55.
20. Bates DW, Boyle DL, Vliet MBV, Schneider J, Leape LL. Relationship between medication error and adverse drug events. J Gen Intern Med. 1995;10(4):199-205.
21. Falconer N, Barras M, Martin J, Cottrell N. Defining and classifying terminology for medication harm: a call for consensus. Eur J Clin Pharmacol. 2019;75(2):137-45.
22. World Health Organization WHO. The importance of pharmacovigilance. Geneva: World Health Organization; 2002. 48p. (NLM classification: QV
38). [cited 17 jun 2018]. Available from:
23. European Medicine Agency and Heads of Medicine Agencies (EMA). Guideline on good pharmacovigilance practices (GVP): Annex I. Definitions
(Rev 4).2017. Available:
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/20 13/05/WC500143294.pdf.
24. Ferner RE. Adverse drug reactions. BMJ.2018;363:k4051
25. Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarifications of terminology. Br J Clin Pharmacol. 2017;83(12):2615-2625.
26. Choonara I. Unlicensed and off-label durg use in children: implications for safety [editorial]. Expert Opin Drug Saf.2004;3(2):81-3.
27. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13(4):306-14.
28. Aronson JK. Medication errors, what they are, how they happen and how to avoid them. QJM. 2009;102(8):513-21.
29. McDowell SE, Ferner HS, Ferner. The pathophysiology of medication errors: how and where they arise. Br J Clin Pharmacol. 2009; 67(6):605-13.
30. Reason J. Human Error. New York: Press Syndicate of the University of Cambridge; 1990. 302p.
31. Fortescue EB, Kaushal R, Landrigan CP, McKenna KJ, Clapp MD, Frederico F, Goldmann DA, Bates DW. Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. Pediatrics.2003; 111(4 Pt 1):722-9.
32. Zandieh SO, Goldmann DA, Keohane CA, Yoon C, Bates DW, Kaushal R. Risk factors in preventable adverse drug events in pediatric outpatients. J Pediatr.2008;152(2):225-31.
33. Chen CJ. Medication error in pediatrics [editorial]. Pediatr Neonatol.2013;54(1):3-4.
34. Wimmer S, Neubert A, Rascher W. The safety of drug therapy in children. Dtsch Artztebl Int. 2015;112(46):781-787.
35. Ojha S, Choonara I. Medication errors in infants at home. Arch Dis Child.2017;102(10):947-948.
36. Kahn S, Abramson EL. What is new in paediatric medication safety? Arch Dis Child. 2019 ;104(6):596-9
37. Brophy TJ, Spiller HA, Casavant MJ, Chounthirath T, Smith MD, Xiang H. Medication errors reported to US Poison Control Centers, 2000-2012. Clin Toxicol (Phila). 2014;52(8):880-8.
38. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug in the outpatient setting: an 11-year national analysis. Pediatrics. 2009;124(4):e744-50.
39. Neuspiel DR, Taylor MM. Reducing the risk of harm from medication errors in children. Health Serv Insights. 2013;6:47-59.
40. Mira JJ, Lorenzo S, Guilabert M, Navarro I, Pérez-Jover V. A systematic review of patient medication error on self-administering medication at home. Expert Opin Drug Saf. 2015;14(6):815-38
41. Berrier K. Medication errors in outpatient pediatrics. MCN AM J Matern Child Nurs.2016;41(5):280-6.
42. Solanki R, Mondal N, Mahalakshmy T, Bhat V. Medication errors by caregivers at home in neonates dicharged from the neonatal intensive care unit. Arch Dis Child. 2017;102(7):651-654.
43. Kaushal R, Goldmann DA, Keohane CA, Christino M, Honour M, Hale AS, Zigmont K, Lehmann LS, Perrin J, Bates DW. Adverse drug events in pediatric outpatients. Amb Pediatr. 2007; 7(5):383-9.
44. Boztepe H, Özdemir H, Karababa Ç, Yildiz Ö. Administration of oral medication by parents at home. J Clin Nurs. 2016;25(21-22):3345-3353.
45. You MA, Nam SM, Son YJ. Parenteral experiences of medication administration to children at home and undertanding of adverse drug events. J Nurs Res. 2015;23(3):189-96.
46. Yin HS, Mendelsohn AL, Wolf MS, Parker RM, Fierman A, van Shaick L, Bazan IS, Kline MD, Dreyer BP. Parents’ medication adminstration errors. Arch Pediatr Adolesc Med. 2010;164(2):181-186.
47. de Wildt SN. Tibboel D, Leeder JS. Drug metabolism for the paediatrician. Arch Dis Child.2014;99(12):1137-42.
48. Star K, Edwards IR. Pharmacovigilance for children`s sake. Drug Saf.2014;37(2):91-8.
49. Yaffe SJ, Aranda JV. Introduction and historical perspectives. In: Yaffe SJ. Aranda JV. Neonatal and pediatric pharmacology: therapeutic principles in practice. 3rd. Philadelphia: Lippincott Williams & Wilkins; 2005. P.3-8.
50. Sage DP, Kulzar C, Roth W, Liu W, Knipp GT. Persistent pharmacokinetic challenges to pediatric drug development. Front Gent. 2014;5:281.
51. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91(5):796-801.
52. Bouquet E, Star K, Jonville-Béra AP, Durrieu G. Pharmacovigilance in pediatrics. Therapie. 2018;73(2):171-80.
53. Bencheikh RS, Benabdallah G. Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol.2009;67(6):687- 90.
54. Varallo RF, Capucho HC, Planeta CS, Mastroianni PC. Possible adverse drug events leading to hospital admission in a Brazilian teaching hospital. Clinics. 2014;69(3):163-7.
55. World Health Organization. The role of the pharmacist in self-care and self- medication. Geneva: World Health Organization; 1998. [cited 02 jun 2019]. Available from: http://apps.who.int/medicinedocs/pdf/whozip32e/.
56. Bronstein AC, Carlson TS, Neuman T, Schauben JL, Geller RJ. National Poison Data System (NPDS). NPDS Coding User`s Manual. American Association of Poison Control Centers. 2014. Version 3.1. [cited 14 jun 2019]. Available from: https://aapcc.s3.amazonaws.com/pdfs/member- resources/NPDS_Coding_Users_Manual_v3.1_07May2014.pdf
57. World Health Organization WHO. WHO collaboration centre for drugs statistics methodology. Guidelines for ATC classification and DDD assignment [online]. [cited 02 jun 2019]. Available from: https://www.whocc.no/atc_ddd_index/
58. National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP). The taxonomy of medication errors [cited 03 jun
2019]. Available from:
https://www.nccmerp.org/sites/default/files/taxonomy2001-07-31.pdf.
59. Lavon O, Ben-Zeev A, Bentur Y. Medication errors outside healthcare facilities: a national poison centre perspective. Basic Clin Pharmacol Toxicol. 2014;114(3):288-92.
60. Cassidy N, Duggan E, Wiilliams DJO, Tracey J. The epidemiology and type of medication errors reported to the National Poisons Information Centre of Ireland. Clin Toxicol (Phila).2011;49(6):485-91.
61. Tzimenatos L, Bond RG and Pediatric Therapeutic Error Study Group. Severe injury or death in young children form therapeutic errors: a summary of 238 cases from the American Association of Poison Control Centers. Clin Toxicol (Phila). 2009; 47(4):348-54.
62. Taylor D McD, Robinson J, MacLeod D, MacBean CE, Braitberg G. Therapeutic errors among children in the community setting: nature, causes and outcomes. J Paediatr Child Health. 2009;45(5):304-9.
63. Miller MR, Robinson KA, Lubomski LH, Rinke ML, Pronovost PJ. Medication errors in paediatric care: a systematic review of epidemiology and an evaluation of evidence supporting reduction strategy recommendation. Qual Saf Health Care. 2007;16(2):116-26.
64. Aagaard L, Hansen EH. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011. Int J Clin Pharm.2014;36(6):1222-9.
65. Star K, Choonara I. How safe is paracetamol? Arch Dis Child. 2015;100(1):73-74.
66. Eluri M, Spiller HA, Casavant J, Chounthirath T, Conner KA, Smith GA. Analgesic-related medication error reported to US Poison Control Centers. Pain Med. 2018;19(2):2357-2370.
67. Marzuillo P. Guarino S, Barbi E. Paracetamol: a focus for the general pediatrician. Eur J Pediatr. 2014;173(4):415-25.
68. Parand A, Garfield S, Vincent C, Franklin BD. Carer`s medication administration errors in the domiciliary setting: a systematic review. Plos One. 2016;11(12):e0167204.
69. Vieira RJ, Bucaretchi F. Exposição aguda a derivados imidazolínicos em crianças. J Pediatr (Rio J).2003;79(6):519-24.
70. Taketomo CK, Hodding JH, Kraus DM. Pediatric & Neonatal Dosage Handbook. Chicago: Lexicomp, 2016. 2241p.
71. Arrais PSD, Fernandes MEP, Pizzol TSD, Ramos LR, Mengue SS, Luiza VL, Tavares NUL, Farias MR, Oliveira MA, Bertoldi AD. Prevalência da automedicação no Brasil e fatores associados. Rev Saude Pública. 2016;50(suppl2):13s.
72. Pfaffenbach G, Tourinho FSV, Bucaretchi F. Self-medication among children and adolescents. Curr Drug Saf. 2010;5(4):324-8.
73. Gualano MR, Bert F, Stillo M, Galis V, Manzoli L, Siliquini R. Use of self- medication among adolescents: a systematic review and meta-analysis. Eur J Public Health. 2015;25(3):444-50.
74. da Silva H, Giugliani ER. Consumption of medicines among adolescent students: a concern. J Pediatr (Rio J). 2004;80(4):326-32.
75. Glick AF, Farkas JS, Nicholson J, Dreyer BP, Fears M, Bandera C, Stolper T, Gerber N, Yin SH. Parenteral management of discharge instruction: a systematic review. Pediatrics. 2017; 140(2):e20164165.
76. Polaha J, Dalton WT, Lancaster BM. Parenteral report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106-12.
77. Bailey SC, Pandit AU, Yin S, Federman A, Davis TC, Parker RM, Wolf MS. Predictors of misundertanding pediatric liquid medication instruction. Fam Med. 2009;41(10):715-21.
78. Yin SH, Parker RM, Sanders LM, Dreyer BP, Mendelsohn AL, Bailey S, Patel DA, Jimenez JJ, Kim K-Y A, Jacobson K, Hedlund L, Simith MCJ, Harris LM, Mc-Fadden T, Wolf MS. Liquid medication errors and dosing tools: a randomized controlled experiment. Pediatrics. 2016;138(4):e201260357.
79. Urban M, Lesso R, Pelclová. Unitentional pharmaceutical-related medication errors caused by layperson reported to the Toxicological Information Centre in Czech Republic. Clin Pharmacol Toxicol Básico. 2016;119 (1):115-9.
80. Shah K, Barker KA. Out-of-hospital medication error: a 6-year analysis of the national poison data system. Pharmacoepidemiol Drug Saf. 2009;18(11):1080-85.
81. Vial T, Patat A-M, Paret N, Boels N, Torrents R, Nisse P, Kassaion V-B A. Risperindone medication errors in children: an analysis of French poison centres data. Clin Toxicol(Phila).2018;57(5):362-367.
82. Seoane-Vazquez E, Rodriguez-Monguio R, Algahtani S, Schiff G. Exploring the potential for using indications to prevent look-alike and sound-alike drug errors. Exploring the potential for using drug indications to prevente look-alike and sound-alike errors. Exper Opin Drug Saf. 2017;16(10):1103-1109.
83. Souza TT, Godoy RR, Rotta I, Pontarolo R, Fernandez-Llimos F, Correr CJ. Morbidade e mortalidade relacionada a medicamentos no Brasil: revisão sistemática de estudos observacionais. Rev Ciênc Farm Básica Apl. 2014;35(4):519-532.